Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

Harvard Business School
McKinsey
Baxter
Medtronic
Express Scripts
Boehringer Ingelheim

Last Updated: May 27, 2022

CLINICAL TRIALS PROFILE FOR CAPTOPRIL


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Captopril

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00004230 ↗ Captopril in Treating Patients Undergoing Bone Marrow or Stem Cell Transplantation Completed National Cancer Institute (NCI) Phase 3 1999-10-01 RATIONALE: Captopril may protect the lungs from the side effects of bone marrow or stem cell transplantation. PURPOSE: Randomized phase III trial to determine the effectiveness of captopril to lessen the side effects in patients who are undergoing bone marrow or stem cell transplantation following chemotherapy and radiation therapy.
NCT00004230 ↗ Captopril in Treating Patients Undergoing Bone Marrow or Stem Cell Transplantation Completed Northwestern University Phase 3 1999-10-01 RATIONALE: Captopril may protect the lungs from the side effects of bone marrow or stem cell transplantation. PURPOSE: Randomized phase III trial to determine the effectiveness of captopril to lessen the side effects in patients who are undergoing bone marrow or stem cell transplantation following chemotherapy and radiation therapy.
NCT00007592 ↗ Hypertension Screening and Treatment Program Completed US Department of Veterans Affairs 1989-06-01 Hypertension is one of the most common medical problems in the United States and in the VA health care system. It has been well-documented that hypertension can be effectively treated. However, there remain important unresolved clinical questions in the area of antihypertensive treatment. For example, how much is mortality affected by visit compliance, blood pressure control and type of antihypertensive agent? Or, are some regimens associated with more morbidity than others? Or, are there inexpensive regimens that are as effective as more expensive regimens? The amount of data that is available from this demonstration project (currently 6,100 patients) will help address these questions. The answers to these questions should result in better care for veterans with hypertension.
NCT00007592 ↗ Hypertension Screening and Treatment Program Completed VA Office of Research and Development 1989-06-01 Hypertension is one of the most common medical problems in the United States and in the VA health care system. It has been well-documented that hypertension can be effectively treated. However, there remain important unresolved clinical questions in the area of antihypertensive treatment. For example, how much is mortality affected by visit compliance, blood pressure control and type of antihypertensive agent? Or, are some regimens associated with more morbidity than others? Or, are there inexpensive regimens that are as effective as more expensive regimens? The amount of data that is available from this demonstration project (currently 6,100 patients) will help address these questions. The answers to these questions should result in better care for veterans with hypertension.
NCT00077064 ↗ Captopril in Treating Patients With Non-Small Cell Lung Cancer or Limited-Stage Small Cell Lung Cancer That Has Been Previously Treated With Radiation Therapy With or Without Chemotherapy Terminated National Cancer Institute (NCI) Phase 2 2003-06-01 RATIONALE: Captopril is a drug that may be able to decrease side effects caused by radiation therapy, and may improve the quality of life of patients with non-small cell lung cancer or limited-stage small cell lung cancer. PURPOSE: This randomized phase II trial is studying how well captopril works in decreasing side effects and improving the quality of life in patients who have received radiation therapy with or without chemotherapy for stage I, stage II, or stage IIIB non-small cell lung cancer or limited-stage small cell lung cancer.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Captopril

Condition Name

Condition Name for Captopril
Intervention Trials
Hypertension 8
Diabetic Nephropathy 4
Healthy Volunteers 2
Type 2 Diabetes Mellitus 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Captopril
Intervention Trials
Hypertension 10
Diabetes Mellitus 4
Kidney Diseases 4
Diabetic Nephropathies 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Captopril

Trials by Country

Trials by Country for Captopril
Location Trials
United States 47
China 3
Brazil 3
Taiwan 3
Egypt 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Captopril
Location Trials
Ohio 6
Massachusetts 4
Tennessee 3
Illinois 3
Florida 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Captopril

Clinical Trial Phase

Clinical Trial Phase for Captopril
Clinical Trial Phase Trials
Phase 4 14
Phase 3 5
Phase 2/Phase 3 1
[disabled in preview] 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Captopril
Clinical Trial Phase Trials
Completed 21
Unknown status 12
Not yet recruiting 6
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Captopril

Sponsor Name

Sponsor Name for Captopril
Sponsor Trials
National Cancer Institute (NCI) 3
Novartis 3
AstraZeneca 2
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Captopril
Sponsor Trials
Other 52
Industry 9
U.S. Fed 4
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Express Scripts
Merck
Colorcon
Johnson and Johnson
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.